Spotlight On... Can BIO's new heartstrings-tugging ad campaign stem the tide of anti-pharma vitriol?; Management rejig at Ipsen opens slot for new CEO; Reckitt consumer brands fuel sales beat; and more...

The biopharma industry is once again trying to move the national drug conversation beyond cost and profits--this time with an emotional ad campaign featuring patients young and old who've been given longer lives thanks to drug discoveries. Viewers might feel a few tugs on their heartstrings, but will it change their minds? Skeptics doubt it. More from FiercePharmaMarketing

@FiercePharma: Zoetis beats estimates in Q4 but dampens 2016 sales forecast on currency woes. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Eisai bulks up on bulk drugs for Japan's growing generics market. Doubling capacity in India. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI last week: Novartis takes aim at Remicade market with EU biosim rights from Pfizer. More | Follow @CarlyHFierce

> A management shakeup at Paris-based Ipsen ($IPN) has split the roles of chairman and CEO, putting current chief Marc de Garidel in line for non-executive chairman and a brand-new chief executive on tap; deputy CEO Christel Bories is leaving the company. Report

> U.K.-based Reckitt Benckiser saw 2015 sales burgeon on strong consumer health growth. Report | Release (PDF)

> California-based Amgen ($AMGN) rolled out its multiple myeloma drug Kyprolis in the U.K.; the drug has been on the U.S. market for more than three years. Report

> Hedge funder Daniel Loeb upped his stake in Allergan ($AGN) by 50% in the fourth quarter as Pfizer ($PFE) prepared to wrap up its deal for the Ireland-based drugmaker; that deal is expected to close late this year. Report

> Benepali, the biosimilar version of Pfizer and Amgen's Enbrel developed by Samsung Bioepis, launched Monday in the U.K. Report

Medical Device News

@FierceMedDev: ICYMI from FierceDrugDelivery: FDA says drug delivery devices need human factors validation testing. Article | Follow @FierceMedDev

@EmilyWFierce: Pfizer takes a $784M hit with Medicaid pricing settlement. FiercePharma story | Follow @EmilyWFierce

> Theranos sends plan to CMS for solving problems at beleaguered California lab. Report

> Data analysis startup cashes in on precision medicine trend with $45M in tow. Story

> GSK partners with Belgian neurostim startup in bioelectronic medicine research. More

> Stryker bulks up in emergency medicine with $1.3B purchase of Physio-Control. Article

Biotech News

@FierceBiotech: Seven Bridges raises $45M to fuel drive to be the backbone of large-scale genome projects. More from FierceBiotechIT | Follow @FierceBiotech

@JohnCFierce: Got plenty of cash? Market carnage sets up a Darwinian showdown in biotech. Story | Follow @JohnCFierce

@DamianFierce: there must be at least one person at who also had NBA All-Star tickets and is just FURIOUS. | Follow @DamianFierce

> Akarna joins the NASH race with a $15M fundraise. Report

> Tonix tanks on a Phase II flop for its headache drug. News

> CAR-T 2.0: Small studies spotlight promise of a breakthrough upgrade. Article

Animal Health News

> VCA beats on earnings in Q4 with growth in animal hospital and lab businesses. Story

> Startup aims to match ailing pets with clinical trials that could help people, too. More

> Trupanion beats Q4 estimates as vet clinics snap up Express insurance product. Report

> Zoetis beats estimates in Q4 but dampens 2016 sales forecast on currency woes. Article

> Investors applaud Schein's record sales and earnings. Item

Biotech IT News

> Biogen allies with GSK in precompetitive computational biology collaboration. Report

> 10x Genomics strikes deals with Illumina, Agilent and Qiagen. News

> Illumina shares details of semiconductor-based sequencing device. Item

> Seven Bridges raises $45M to fuel drive to be the backbone of large-scale genome projects. Story

> Illumina, Icon land data deals with U.K. mass genome sequencing program. Article

Drug Delivery News

> Early-stage drug delivery implant targeting pancreatic cancer tumors showing promise. Report

> Shape, flexibility of nanoparticles give them an edge against cancer. More

> Amgen deploys West Pharma vials to store its injectable cancer med Imlygic. Item

> Gold nanoparticle clusters and bursts of infrared light eliminate post-surgery tumor cells. Story

> BioCryst stock in dumps after it terminates soft gel arm of its rare disease candidate. Article

Pharma Manufacturing News

> Pfizer recalls children's Advil in Canada; 'clumps' could cause dosing mistakes. More

> Vet drugmaker Chanelle Group putting €70M into Ireland plant. Item

> Perrigo recalling 200M units of antifungus drug over labeling mishap. Report

> Sun to ask for FDA reinspection of troubled Halol plant. Story

> Buffalo, NY-based drug developer says it will build biologics plant, hire 900. Article

Pharma Asia News

> Indonesia clears decks for foreign API manufacturers. Article

> China push to bring biotech talent home is paying off. More

> China healthcare exports need marketing, quality push after acquisitions: L.E.K. Story

> China renews consolidation drive for drug manufacture, wants TCM push. Article

> India's MedGenome pledges $10M for South Asia sequencing effort. Report

And Finally... Three U.S. agencies are joining forces to investigate claims that artificial turf fields and playgrounds that use bits of recycled tires may be health hazards. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.